Immunoconjugates (Immunoconjugate)

Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.

Also Known As:

Networked: 726 relevant articles (75 outcomes, 103 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Reilly, Raymond M: 12 articles (11/2015 - 03/2006)
2.	Dahle, Jostein: 12 articles (01/2015 - 02/2006)
3.	Brechbiel, Martin W: 11 articles (02/2011 - 05/2002)
4.	Seidl, Christof: 10 articles (03/2015 - 05/2003)
5.	Goldenberg, David M: 10 articles (01/2015 - 11/2003)
6.	Larsen, Roy H: 8 articles (01/2015 - 02/2006)
7.	Damle, Nitin K: 8 articles (04/2011 - 08/2003)
8.	Bruchertseifer, Frank: 7 articles (03/2015 - 08/2007)
9.	Morgenstern, Alfred: 7 articles (03/2015 - 12/2006)
10.	Press, Oliver W: 7 articles (10/2014 - 06/2007)

Related Diseases

1.	Neoplasms (Cancer) 10/05/2015 - "Ultimately, this pretargeted PET imaging strategy boasts a dramatically improved pharmacokinetic profile compared to our first generation system and is capable of clearly delineating tumor tissue with high image contrast at only a fraction of the radiation dose created by directly labeled radioimmunoconjugates. " 12/01/1998 - "To achieve maximum retention of radiolabel in tumor and a more rapid clearance of radioisotope from normal tissues, six linker immunoconjugates were evaluated in studies using nude mice and beagle dogs. " 01/01/2007 - "This can be achieved by rapid clearance of radiometal in the circulation after accumulation of radioimmunoconjugates (RIC) in the tumor. " 01/01/2003 - "Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments, particularly for solid tumors." 06/01/1987 - "However, many obstacles still have to be overcome before immunoconjugates become a valuable agent in the treatment of human diseases including cancer."
2.	Lymphoma (Lymphomas) 01/01/1997 - "Preliminary clinical studies have clearly demonstrated the ability of radioimmunoconjugates, especially when administered at high dose followed by bone marrow rescue, to induce durable complete remission in patients with non-Hodgkin's lymphomas refractory to conventional therapies. " 12/15/1997 - "Lymphomas have been shown to be responsive to 131I immunoconjugates in studies conducted in mice and patients. " 02/15/2010 - "One strategy involves the use of radiolabeled immunoconjugates that specifically localize radiation delivery to sites of lymphoma while minimizing toxicity to normal tissues. " 09/15/2007 - "In vitro, this radioimmunoconjugate killed lymphoma cells at Becquerel per milliliter (Bq/mL) levels. " 02/01/2006 - "The alpha-emitting radioimmunoconjugate (227)Th-DOTA-p-benzyl-rituximab is a new potential anti-lymphoma agent that might overcome some of these difficulties. "
3.	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/01/2004 - "The safety and efficacy of anti-CD20 in the treatment of indolent and aggressive B-cell non-Hodgkin lymphoma at any stage of disease, either as a single agent or as part of multimodality regimes, as an unconjugated antibody or as radioimmunoconjugate have changed dramatically our treatment strategies. " 01/01/2000 - "Studies further defined the role monoclonal antibody treatment for non-Hodgkin's lymphoma and more mature data were presented on both unconjugated antibody therapy and radioimmunoconjugates. " 01/01/2015 - "177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. " 03/01/2013 - "Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma." 01/01/2003 - "To date, 90Y-ibritumomab tiuxetan and 131I-tositumomab are the only FDA-approved, and most extensively studied, radioimmunoconjugates for RIT of non-Hodgkin's lymphoma (NHL). "
4.	Carcinoma (Carcinomatosis) 01/01/1997 - "Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates." 10/15/1991 - "In this study, the breast carcinoma-reactive monoclonal antibody 15A8 and a site-specific immunoconjugate of the antibody, 15A8-glycyl-tyrosyl-(N-epsilon-diethylenetriamine pentaacetic acid)-lysine (15A8-GYK-DTPA), were characterized by immunohistological methods for reactivity with normal and neoplastic human tissues and normal cynomolgus monkey tissues. " 08/01/2013 - "We examined micrometastases from a murine model of ovarian carcinoma after injection of a radioimmunoconjugate labeled with (211)At for TAT. " 09/02/2009 - "The 1C1-mcMMAF immunoconjugate had antitumor activity in preclinical models of ovarian carcinoma." 08/15/2003 - "The radioimmunoconjugate was tested for immunoreactivity, internalization, and cytotoxicity using a human ovarian carcinoma cell line, SKOV3. "
5.	Breast Neoplasms (Breast Cancer) 10/01/1999 - "Radioimmunoconjugates of 170H.82 (m170), a panadenocarcinoma monoclonal antibody, are effective for imaging primary and metastatic breast cancer. " 10/01/2015 - "These radioimmunoconjugates (230 and 460 kBq) showed a significant higher cytotoxicity to SKBR3 human breast cancer cells overexpressing HER2 compared to (111)In-trastuzumab. " 07/01/2014 - "Immunoconjugates in the treatment of breast cancer." 12/06/2010 - "These immunoconjugates were analyzed by SDS-PAGE, and their immunoreactivity was assessed by flow cytometry using HER-2 overexpressing SK-BR-3 breast cancer cells. " 01/01/2007 - "Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells."

Related Drugs and Biologics

1.	Antigens
2.	Antibodies
3.	Doxorubicin (Adriamycin)
4.	Immunotoxins (Immunotoxin)
5.	Monoclonal Antibodies
6.	Ricin
7.	rituximab (Mabthera)
8.	CMC544 (Inotuzumab Ozogamicin)
9.	taxane
10.	tumor-associated antigen 72

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Radioimmunotherapy
3.	Transplants (Transplant)
4.	Immunotherapy
5.	Intraperitoneal Injections